|
1
|
Davies C, Pan H, Godwin J, et al; Adjuvant
Tamoxifen. Longer Against Shorter (ATLAS) Collaborative Group:
Long-term effects of continuing adjuvant tamoxifen to 10 years
versus stopping at 5 years after diagnosis of oestrogen
receptor-positive breast cancer: ATLAS, a randomised trial. Lancet.
381:805–816. 2013. View Article : Google Scholar :
|
|
2
|
Jordan VC: Tamoxifen: the herald of a new
era of preventive therapeutics. J Natl Cancer Inst. 89:747–749.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jones ME, van Leeuwen FE, Hoogendoorn WE,
et al: Endometrial cancer survival after breast cancer in relation
to tamoxifen treatment: pooled results from three countries. Breast
Cancer Res. 14:R912012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cohen I: Endometrial pathologies
associated with postmenopausal tamoxifen treatment. Gynecol Oncol.
94:256–266. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bergman L, Beelen ML, Gallee MP, Hollema
H, Benraadt J and van Leeuwen FE: Risk and prognosis of endometrial
cancer after tamoxifen for breast cancer. Comprehensive Cancer
Centres’ ALERT Group Assessment of Liver and Endometrial cancer
Risk following Tamoxifen. Lancet. 356:881–887. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Swerdlow AJ and Jones ME; British
Tamoxifen Second Cancer Study Group. Tamoxifen treatment for breast
cancer and risk of endometrial cancer: a case-control study. J Natl
Cancer Inst. 97:375–384. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berlière M, Charles A, Galant C and Donnez
J: Uterine side effects of tamoxifen: a need for systematic
pretreatment screening. Obstet Gynecol. 91:40–44. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garuti G, Cellani F, Centinaio G, Sita G,
Nalli G and Luerti M: Baseline endometrial assessment before
tamoxifen for breast cancer in asymptomatic menopausal women.
Gynecol Oncol. 98:63–67. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
López DM, Fernández YG, Sánchez AV,
Alvarez MI, Reynaldo MI and Delgado RC: Baseline hysteroscopic
assessment of endometrium in asymptomatic postmenopausal women with
estrogen receptor-positive breast cancer. Menopause. 20:64–71.
2013. View Article : Google Scholar
|
|
10
|
Garuti G, Cellani F, Centinaio G, Sita G,
Nalli G and Luerti M: Histopathologic behavior of endometrial
hyperplasia during tamoxifen therapy for breast cancer. Gynecol
Oncol. 101:269–273. 2006. View Article : Google Scholar
|
|
11
|
Bland AE, Calingaert B, Secord AA, et al:
Relationship between tamoxifen use and high risk endometrial cancer
histologic types. Gynecol Oncol. 112:150–154. 2009. View Article : Google Scholar
|
|
12
|
Shang Y and Brown M: Molecular
determinants for the tissue specificity of SERMs. Science.
295:2465–2468. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fong CJ, Burgoon LD, Williams KJ, Forgacs
AL and Zacharewski TR: Comparative temporal and dose-dependent
morphological and transcriptional uterine effects elicited by
tamoxifen and ethynylestradiol in immature, ovariectomized mice.
BMC Genomics. 8:1512007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang H, McElrath T, Tong W and Pollard
JW: The molecular basis of tamoxifen induction of mouse uterine
epithelial cell proliferation. J Endocrinol. 184:129–140. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mourits MJ, Ten Hoor KA, van der Zee AG,
Willemse PH, de Vries EG and Hollema H: The effects of tamoxifen on
proliferation and steroid receptor expression in postmenopausal
endometrium. J Clin Pathol. 55:514–519. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mourits MJ, Hollema H, de Vries EG, Ten
Hoor KA, Willemse PH and Van Der Zee AG: Apoptosis and
apoptosis-associated parameters in relation to tamoxifen exposure
in postmenopausal endometrium. Hum Pathol. 33:341–346. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vaillant F, Merino D, Lee L, et al:
Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen
receptor-positive breast cancer. Cancer Cell. 24:120–129. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Acconcia F, Barnes CJ and Kumar R:
Estrogen and tamoxifen induce cytoskeletal remodeling and migration
in endometrial cancer cells. Endocrinology. 147:1203–1212. 2006.
View Article : Google Scholar
|
|
19
|
Tsai CL, Wu HM, Lin CY, et al: Estradiol
and tamoxifen induce cell migration through GPR30 and activation of
focal adhesion kinase (FAK) in endometrial cancers with low or
without nuclear estrogen receptor α (ERα). PLoS One. 8:e729992013.
View Article : Google Scholar
|
|
20
|
Taylor AH, Kalathy V and Habiba M:
Estradiol and tamoxifen enhance invasion of endometrial stromal
cells in a three-dimensional coculture model of adenomyosis. Fertil
Steril. 101:288–293. 2014. View Article : Google Scholar
|
|
21
|
Cooke PS, Buchanan DL, Young P, et al:
Stromal estrogen receptors mediate mitogenic effects of estradiol
on uterine epithelium. Proc Natl Acad Sci U S A. 94:6535–6540.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Williams GM, Iatropoulos MJ, Djordjevic MV
and Kaltenberg OP: The triphenylethylene drug tamoxifen is a strong
liver carcinogen in the rat. Carcinogenesis. 14:315–317. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hard GC, Williams GM and Iatropoulos MJ:
Tamoxifen and liver cancer. Lancet. 342:444–445. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Carthew P, Martin EA, White IN, et al:
Tamoxifen induces short-term cumulative DNA damage and liver tumors
in rats: promotion by phenobarbital. Cancer Res. 55:544–547.
1995.PubMed/NCBI
|
|
25
|
Hirsimäki P, Hirsimäki Y, Nieminen L and
Payne BJ: Tamoxifen induces hepatocellular carcinoma in rat liver:
a 1-year study with two antiestrogens. Arch Toxicol. 67:49–54.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vancutsem PM, Lazarus P and Williams GM:
Frequent and specific mutations of the rat p53 gene in
hepatocarcinomas induced by tamoxifen. Cancer Res. 54:3864–3867.
1994.PubMed/NCBI
|
|
27
|
Furr BJ and Jordan VC: The pharmacology
and clinical uses of tamoxifen. Pharmacol Ther. 25:127–205. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carmichael PL, Sardar S, Crooks N, et al:
Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA
adducts in the human endometrium. Carcinogenesis. 20:339–342. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Beland FA, Churchwell MI, Doerge DR, et
al: Electrospray ionization-tandem mass spectrometry and
32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J
Natl Cancer Inst. 96:1099–1104. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shibutani S, Ravindernath A, Suzuki N,
Terashima I, Sugarman SM, Grollman AP and Pearl ML: Identification
of tamoxifen-DNA adducts in the endometrium of women treated with
tamoxifen. Carcinogenesis. 21:1461–1467. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shibutani S, Suzuki N, Terashima I,
Sugarman SM, Grollman AP and Pearl ML: Tamoxifen-DNA adducts
detected in the endometrium of women treated with tamoxifen. Chem
Res Toxicol. 12:646–653. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Andersson H, Helmestam M, Zebrowska A,
Olovsson M and Brittebo E: Tamoxifen-induced adduct formation and
cell stress in human endometrial glands. Drug Metab Dispos.
38:200–207. 2010. View Article : Google Scholar
|
|
33
|
Fles R, Hoogendoorn WE, Platteel I, et al:
Genomic profile of endometrial tumors depends on morphological
subtype, not on tamoxifen exposure. Genes Chromosomes Cancer.
49:699–710. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yeramian A, Moreno-Bueno G, Dolcet X, et
al: Endometrial carcinoma: molecular alterations involved in tumor
development and progression. Oncogene. 32:403–413. 2013. View Article : Google Scholar
|
|
35
|
Lagarda H, Catasus L, Arguelles R,
Matias-Guiu X and Prat J: K-ras mutations in endometrial carcinomas
with microsatellite instability. J Pathol. 193:193–199. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sun H, Enomoto T, Shroyer KR, et al:
Clonal analysis and mutations in the PTEN and the K-ras genes in
endometrial hyperplasia. Diagn Mol Pathol. 11:204–211. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Prasad M, Wang H, Douglas W, Barakat RR
and Ellenson LH: Molecular genetic characterization of
tamoxifen-associated endometrial cancer. Gynecol Oncol. 96:25–31.
2005. View Article : Google Scholar
|
|
38
|
Turbiner J, Moreno-Bueno G, Dahiya S, et
al: Clinicopathological and molecular analysis of endometrial
carcinoma associated with tamoxifen. Mod Pathol. 21:925–936. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yasue A, Hasegawa K and Udagawa Y: Effects
of tamoxifen on the endometrium and its mechanism of
carcinogenicity. Hum Cell. 24:65–73. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Holtz D, Ramondetta LM, Burke TW, Palazzo
JP, Dunton CJ, Atkinson EN and Broaddus RR: PTEN expression in
tamoxifen-associated endometrial cancers. Anticancer Res.
22:2945–2948. 2002.
|
|
41
|
Wallén M, Tomás E, Visakorpi T, Holli K
and Mäenpää J: Endometrial K-ras mutations in postmenopausal breast
cancer patients treated with adjuvant tamoxifen or toremifene.
Cancer Chemother Pharmacol. 55:343–346. 2005. View Article : Google Scholar
|
|
42
|
Hachisuga T, Miyakawa T, Tsujioka H,
Horiuchi S, Emoto M and Kawarabayashi T: K-ras mutation in
tamoxifen-related endometrial polyps. Cancer. 98:1890–1897. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hachisuga T, Tsujioka H, Horiuchi S, Udou
T, Emoto M and Kawarabayashi T: K-ras mutation in the endometrium
of tamoxifen-treated breast cancer patients, with a comparison of
tamoxifen and toremifene. Br J Cancer. 92:1098–1103. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Miranda SP, Traiman P, Cândido EB, et al:
Expression of p53, Ki-67, and CD31 proteins in endometrial polyps
of postmenopausal women treated with tamoxifen. Int J Gynecol
Cancer. 20:1525–1530. 2010.PubMed/NCBI
|
|
45
|
Brzozowski AM, Pike AC, Dauter Z, et al:
Molecular basis of agonism and antagonism in the oestrogen
receptor. Nature. 389:753–758. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
46
|
McDonnell DP: The molecular determinants
of estrogen receptor pharmacology. Maturitas. 48(Suppl 1): S7–12.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shah YM and Rowan BG: The Src kinase
pathway promotes tamoxifen agonist action in Ishikawa endometrial
cells through phosphorylation-dependent stabilization of estrogen
receptor (alpha) promoter interaction and elevated steroid receptor
coactivator 1 activity. Mol Endocrinol. 19:732–748. 2005.
View Article : Google Scholar
|
|
48
|
Elkas J, Armstrong A, Pohl J, Cuttitta F,
Martínez A and Gray K: Modulation of endometrial steroid receptors
and growth regulatory genes by tamoxifen. Obstet Gynecol.
95:697–703. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mehasseb MK, Bell SC and Habiba MA: The
effects of tamoxifen and estradiol on myometrial differentiation
and organization during early uterine development in the CD1 mouse.
Reproduction. 138:341–350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lin SL, Yan LY, Zhang XT, et al:
ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist
action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt
pathways. PLoS One. 5:e90132010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Filardo EJ, Quinn JA, Frackelton AR Jr and
Bland KI: Estrogen action via the G protein-coupled receptor,
GPR30: stimulation of adenylyl cyclase and cAMP-mediated
attenuation of the epidermal growth factor receptor-to-MAPK
signaling axis. Mol Endocrinol. 16:70–84. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Smith HO, Leslie KK, Singh M, Qualls CR,
Revankar CM, Joste NE and Prossnitz ER: GPR30: a novel indicator of
poor survival for endometrial carcinoma. Am J Obstet Gynecol.
196:3862007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Vivacqua A, Bonofiglio D, Recchia AG,
Musti AM, Picard D, Andò S and Maggiolini M: The G protein-coupled
receptor GPR30 mediates the proliferative effects induced by
17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
Mol Endocrinol. 20:631–646. 2006. View Article : Google Scholar
|
|
54
|
Ignatov T, Eggemann H, Semczuk A, et al:
Role of GPR30 in endometrial pathology after tamoxifen for breast
cancer. Am J Obstet Gynecol. 203:5952010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tamm-Rosenstein K, Simm J, Suhorutshenko
M, Salumets A and Metsis M: Changes in the transcriptome of the
human endometrial Ishikawa cancer cell line induced by estrogen,
progesterone, tamoxifen, and mifepristone (RU486) as detected by
RNA-sequencing. PLoS One. 8:e689072013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pole JC, Gold LI, Orton T, Huby R and
Carmichael PL: Gene expression changes induced by estrogen and
selective estrogen receptor modulators in primary-cultured human
endometrial cells: signals that distinguish the human carcinogen
tamoxifen. Toxicology. 206:91–109. 2005. View Article : Google Scholar
|
|
57
|
Gielen SC, Santegoets LA, Hanifi-Moghaddam
P, Burger CW and Blok LJ: Signaling by estrogens and tamoxifen in
the human endometrium. J Steroid Biochem Mol Biol. 109:219–223.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ferguson SE, Olshen AB, Viale A, Awtrey
CS, Barakat RR and Boyd J: Gene expression profiling of
tamoxifen-associated uterine cancers: evidence for two molecular
classes of endometrial carcinoma. Gynecol Oncol. 92:719–725. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gielen SC, Kühne LC, Ewing PC, Blok LJ and
Burger CW: Tamoxifen treatment for breast cancer enforces a
distinct gene-expression profile on the human endometrium: an
exploratory study. Endocr Relat Cancer. 12:1037–1049. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Clarke R, Cook KL, Hu R, et al:
Endoplasmic reticulum stress, the unfolded protein response,
autophagy, and the integrated regulation of breast cancer cell
fate. Cancer Res. 72:1321–1331. 2012.PubMed/NCBI
|
|
61
|
Cook KL, Shajahan AN, Wärri A, Jin L,
Hilakivi-Clarke LA and Clarke R: Glucose-regulated protein 78
controls cross-talk between apoptosis and autophagy to determine
antiestrogen responsiveness. Cancer Res. 72:3337–3349. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Gomez BP, Riggins RB, Shajahan AN, et al:
Human X-box binding protein-1 confers both estrogen independence
and antiestrogen resistance in breast cancer cell lines. FASEB J.
21:4013–4027. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Tergas AI, Buell-Gutbrod R, Gwin K, et al:
Clinico-pathologic comparison of type II endometrial cancers based
on tamoxifen exposure. Gynecol Oncol. 127:316–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Erdemoglu E, Güney M, Take G, Giray SG and
Mungan T: RAD001 (Everolimus) Can prevent tamoxifen-related
endometrial and stromal hyperplasia. Int J Gynecol Cancer.
19:375–379. 2009. View Article : Google Scholar : PubMed/NCBI
|
